Pancreatic Adenocarcinoma Metastatic Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

Also known as: Metastatic Pancreatic Adenocarcinoma / Pancreatic carcinoma metastatic

IndicationStatusPhase
DBCOND0060224 (Pancreatic Adenocarcinoma Metastatic)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03331562A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic CancerTreatment
NCT02826486Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202)Treatment
NCT03006302Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas CancerTreatment